combination therapy with glp-1 receptor agonist and sglt2 inhibitor Without Inhibitors in Patients With Type 2 Diabetes Diabetic Agents, From Metformin to
Description
doi:10.1111/bcp.15816 186
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L
These are not the therapeutic targets of GLP-1 or GLP-1/GIP therapy
3) exenatide OR lixisenatide OR liraglutide OR semaglutide OR albiglutide OR dulaglutide OR efpeglenatide
The consent is not adequate, Caplan said
